Edition:
India

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.43USD
9:33pm IST
Change (% chg)

$-0.03 (-2.05%)
Prev Close
$1.46
Open
$1.52
Day's High
$1.52
Day's Low
$1.40
Volume
14,516
Avg. Vol
70,909
52-wk High
$4.25
52-wk Low
$0.63

Select another date:

Thu, Mar 15 2018

BRIEF-Capricor Q4 Earnings Per Share $0.42

* CAPRICOR PRESENTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE

BRIEF-Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT Designation

* CAPRICOR THERAPEUTICS SAYS ‍FDA HAS GRANTED CAP-1002 REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION - SEC FILING Source text : (http://bit.ly/2s6RQ09) Further company coverage:

BRIEF-Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing

* CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING

BRIEF-Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002

* CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002

BRIEF-Capricor Therapeutics reports Q3 loss per share $0.12

* Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program

BRIEF-Capricor says results from Duchenne muscular dystrophy trial to be presented at AHA late-breaking session

* Capricor announces 12-month results from HOPE-1 trial in Duchenne muscular dystrophy to be presented at AHA late-breaking session Source text for Eikon: Further company coverage:

Select another date: